Biochemists confirm existence of theoretical genetic disorder

January 8, 2018, Bielefeld University
By studying the cell cultures, Dr. Björn Kowalewski and Mai-Britt Ilse confirmed that the patient's mutated gene has lost it function. Credit: Bielefeld University

Thanks to the sequencing of the human genome, scientists can now discover potential disorders for which there are no known patients. One such disorder is MPS III-E, originally also called Dierks's disorder after its discoverer. Doctors at the Hadassah-Hebrew University Medical Center in Jerusalem (Israel) found consistent symptoms of progressive blindness in three patient families that indicated the presence of a previously unknown genetic defect. Genomic analyses at the University of Lausanne (Switzerland) delivered a candidate gene on which Professor Dr. Thomas Dierks from Bielefeld University had already published a research article in 2012. Studies by Dierks' research team now revealed that these patients indeed suffer from MPS III-E. The researchers are now presenting their analysis in the journal Genetics in Medicine.

Through biochemical studies and genetic analyses, it was finally possible to confirm the disorder in five from the Israeli families. "These persons have increasingly poor vision due to progressive retinal atrophy. They also develop an inner ear hearing impairment," reports Dierks. "These are the same symptoms—alongside others—that we also found among mice in our earlier studies."

The scientists at Bielefeld had studied the disorder in mice. In these animals, they switched off the gene responsible for producing the arylsulfatase G. This ensured that the carbohydrate could no longer be fully degraded. "As a result, the carbohydrate accumulated in the cells," explains Thomas Dierks. This accumulation takes place in the lysosomes, the 'recycling plants' of the cells. Due to this metabolic dysfunction, the breakdown also of other substances such as lipids and proteins gradually comes to a standstill. The accumulation then increases the size of the lysosome until it destroys the cell—and that brings about the disorder.

To determine whether the mutated gene in the patients actually does lead to the enzyme defect, Dierks' team studied the patient gene in a cell culture. This culture produced the enzyme (arylsulfatase G). They found that "the enzyme actually was seriously damaged. It is unable to break down the heparan sulfate," says Dierks.

The researchers were surprised the first time they found out about the Israeli patients in April. "They did not start to show the symptoms before the age of 40. Based on our studies with mice, we assumed that the symptoms would emerge much earlier—perhaps after ten years," says Dierks. His explanation for this delay in the outbreak of the disorder is that large parts of the heparan sulfate molecule can be degraded without arylsulfatase G. "Hence, it takes more time to accumulate."

Now that the cause of the symptoms is known, it is possible to think about an for the patients. "The required enzyme can be produced biotechnologically with the help of cell cultures," says Dierks. For the treatment, the enzyme is injected intravenously. It is then carried through the body in the blood and should break down the heparan sulfate in the tissues. "However, the brain is hard for the enzyme to reach. Moreover, the disorder has to be diagnosed through gene tests before the symptoms appear if treatment is to commence before damage has become irreparable." Now that the symptoms resulting from this hereditary disorder in humans are known, Dierks expects that the genetic defect will also be diagnosed in more people. "Further patients should be found particularly among the unexplained cases with Usher syndrome—this indicates a combined loss of vision and hearing."

Explore further: New gene therapy targets brain disorders

More information: Samer Khateb et al, A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans, GENETICS in MEDICINE (2018). DOI: 10.1038/gim.2017.227

Related Stories

New gene therapy targets brain disorders

November 9, 2017
UNSW researchers have tailored gene therapy for a rare genetic disorder called Canavan disease, and say it could eventually be adapted to treat other inherited disorders affecting the brain.

New biomarker found for group of rare metabolic diseases

August 7, 2017
A newly discovered biomarker associated with a rare metabolic disorder may facilitate better diagnosis and identification of new drugs for clinical trials for the disease, according to researchers in the Perelman School of ...

Complex mechanisms in Gaucher disease unravelled

March 30, 2017
Gaucher disease is a genetic disorder of lipid metabolism. Sphingosine, a compound as enigmatic as the sphinx, plays a key role in this metabolic disorder. Scientists from the Bonn research center caesar have identified some ...

Recommended for you

Variants in non-coding DNA contribute to inherited autism risk

April 19, 2018
In recent years, researchers have firmly established that gene mutations appearing for the first time, called de novo mutations, contribute to approximately one-third of cases of autism spectrum disorder (ASD). In a new study, ...

Researchers discover link between gene variation and language

April 18, 2018
What shapes the basic features of a language?

Natural selection still at work in humans

April 18, 2018
Evolution has shaped the human race, with University of Queensland researchers finding signatures of natural selection in the genome that influence traits associated with fertility and heart function.

Gene therapy for beta-thalassemia safe, effective in people

April 18, 2018
In a powerful example of bench-to-bedside science showing how observations made in the lab can spark life-altering therapies in clinic, an international team of clinician-investigators has announced that gene therapy for ...

Potential lines of attack against prostate cancer

April 17, 2018
Researchers from The University of East Anglia (UEA) have contributed to the world's largest study into genes that drive prostate cancer – identifying 80 molecular weaknesses that could be targeted by drugs to treat the ...

Epstein-Barr virus linked to seven serious diseases

April 16, 2018
A far-reaching study conducted by scientists at Cincinnati Children's reports that the Epstein-Barr virus (EBV)—best known for causing mononucleosis—also increases the risks for some people of developing seven other major ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gzurbay
not rated yet Jan 13, 2018
12,000 diseases - oops, sorry 12,001. Looks like possibly "NATURAL death could be on the way out" - until of course medicine works through the list, - this does beg the question "what the hell was god doing with all that time before creation?" Working on a tan?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.